Chicago, ILNCT07819773Now EnrollingIRB Ready

Generalized Anxiety Disorder (GAD) Clinical Trial in Chicago, IL

Access cutting-edge generalized anxiety disorder (gad) treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by BTL Industries Ltd.

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access generalized anxiety disorder (gad) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related generalized anxiety disorder (gad) treatment provided free

Apply for This Chicago Location

Check if you qualify for this generalized anxiety disorder (gad) clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Generalized Anxiety Disorder (GAD) Study in Chicago

The goal of this clinical trial is to learn if treatment with the BTL-699-2 device (non-invasive repetitive transcranial magnetic stimulation) can decrease anxiety symptoms in adults (aged 22 years and older) diagnosed with Generalized Anxiety Disorder (GAD). The main questions it aims to answer are: Does the accelerated treatment protocol using the BTL-699-2 device reduce self-reported anxiety symptoms (as measured by the GAD-7 scale) 3 months after the final treatment? What are the safety and side effects associated with the use of the BTL-699-2 device during this accelerated protocol? Researchers will compare the active treatment group (Group A, receiving stimulation intensity of up to 70% of the individual's motor threshold) to a sham control group (Group B, receiving an inactive stimulation intensity of 5% of their motor threshold) to see if the active brain stimulation works to treat Generalized Anxiety Disorder. Participants will: * Attend a screening/baseline visit to confirm GAD diagnosis (using the MINI diagnostic interview), review medical history, and establish their individual motor threshold. * Complete 8 study treatment visits scheduled twice weekly (2 to 4 days apart) over approximately 4 weeks. Each visit will consist of two consecutive 19-minute treatment sessions delivered at least 15 minutes apart (for a total of 16 treatments). * Complete self-reported and clinician-reported questionnaires assessing anxiety (GAD-7, HAM-A), depressive symptoms (PHQ-9), well-being (WEMWBS), suicidal risk (CSSRS), clinical improvement (CGI-I, PGI-I), and treatment comfort/satisfaction (TCQ, SSQ) at designated baseline, treatment, and follow-up visits. * Undergo a urine pregnancy test at baseline and once weekly (every other treatment visit) if they are women of childbearing potential. * Attend 2 follow-up visits scheduled at 1 month and 3 months after the final treatment to evaluate long-term outcomes and safety

Sponsor: BTL Industries Ltd.

Who Can Participate

Inclusion Criteria

Age ≥ 22 years
A diagnosis of GAD according to DSM-5 criteria, confirmed by a qualified clinician at screening
Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the right thumb
Subjects willing and able to abstain from partaking in any treatments other than the pre-procedure therapy regime for the treatment of anxiety, including non-invasive brain stimulation treatments other than the study procedure during study participation
Willingness to comply with study instructions and to return to the clinic for the required visits
Women of child-bearing potential\
are required to use birth control measures during the whole duration of the study
If applicable, subjects must be maintained on their pre-study psychotherapeutic regimen and any prescribed chronic medications at a stable therapeutic dose for ≥4 weeks prior to enrollment, with no dose or usage frequency changes permitted during the study

Exclusion Criteria

Metallic objects in or near the head rTMS devices are contraindicated for use in patients who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head or within 12 in (30 cm) of the treatment coil.\
Implanted stimulator devices
Active or inactive implants (including device leads), including deep brain stimulators, cochlear implants, ocular implants and vagus nerve stimulators. Contraindicated use could result in serious injury or death.
Application in the heart area
Persons with a tendency to seizure (e.g., persons suffering from hypotonia and epilepsy)
Anticoagulation therapy
Severe or life-threatening condition
Pulmonary insufficiency
Heart disorders
Renal insufficiency
Decompensated\*\
hemorrhagic conditions
Decompensated\*\
blood coagulation disorders
Decompensated\*\
cardiovascular diseases
Malignant tumor or benign tumor
Active suicidal intent\*\*\
History of suicide attempts in the last 3 years
History or concurrent use of electroconvulsive therapy or vagus nerve stimulation
Substance-induced depression or depression secondary to a general medical condition
Seasonal affective disorder
Substance abuse
Substance dependence 3 months prior
A psychotic disorder including schizoaffective disorder, bipolar disease, borderline personality disorder or major depression with psychotic features
Neurological disorders, including a history of seizures, cerebrovascular disease, primary or secondary tumors in CNS, cerebral aneurysm, dementia, or movement disorders
Ongoing intake disorders such as bulimia or anorexia, or intake disorder in the past fiscal year
History of increased intracranial pressure or head trauma
Any other disease or condition at the investigator's discretion that may pose risk to the patient or compromise the study
Examples include cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, jewelry and hair barrettes. Failure to follow this restriction could result in serious injury or death. Certain exceptions apply to mouth implants, such as standard amalgam dental fillings, single post dental implants, dental bridge work, and braces. If these items are present, the therapy can still be administered.
By means of decompensation, it means a patient with a proven medical history of a decompensated health condition and long-term medication. Patients who use certain medications only for preventive purposes, without any proven previous health condition failure, are not considered contraindicated.
Defined by a score of Level 4 or Level 5 on the Columbia-Suicide Severity Rating Scale (CSSRS).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT07819773) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Generalized Anxiety Disorder (GAD) Treatment Options in Chicago, IL

If you're searching for generalized anxiety disorder (gad) treatment options in Chicago, IL, this clinical trial (NCT07819773) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced generalized anxiety disorder (gad) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all generalized anxiety disorder (gad) clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Chicago, IL

See all alzheimers disease clinical trials recruiting in Chicago — not just this study.

Browse Alzheimers Disease Trials in Chicago →

Browse More Trials by Condition

Alzheimers Disease TrialsEssential Tremor TrialsAnxiety TrialsRheumatoid Arthritis TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL